Physician profile
Korey R Ullrich
NPI 1639342124
$466,744.07
in general payments reported to CMS, 2019-2025
35 companies · $31.22 in 2025
The $31.22 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103K · 2020: $38K · 2021: $17K · 2022: $91K · 2023: $122K · 2024: $96K · 2025: $31.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $160K · Travel and Lodging: $43K · Food and Beverage: $11K · Consulting Fee: $3,575 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $160,100.00 |
| Travel and Lodging | $42,973.79 |
| Food and Beverage | $11,139.50 |
| Consulting Fee | $3,575.00 |
| Education | $213.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $215,773.85 | 2019-2024 | Taltz |
| Amgen INC. | $145,186.36 | 2019-2024 | Evenity, Prolia, Enbrel |
| Horizon Therapeutics Plc | $36,291.13 | 2019-2023 | Krystexxa |
| Abbvie INC. | $18,904.59 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Novartis Pharmaceuticals Corporation | $10,884.91 | 2019-2024 | |
| Janssen Biotech, INC. | $8,720.74 | 2019-2024 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $7,199.45 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $5,883.61 | 2021-2022 | |
| Glaxosmithkline, LLC. | $5,347.30 | 2019-2024 | Benlysta, Nucala |
| Ucb, INC. | $3,162.76 | 2019-2024 | Cimzia, Bimzelx |
| Regeneron Healthcare Solutions, INC. | $3,041.78 | 2019 | |
| Sandoz INC. | $1,596.00 | 2019 | |
| Pfizer INC. | $859.91 | 2019-2024 | |
| Radius Health, INC. | $779.61 | 2019-2024 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $715.25 | 2019-2024 | Orencia |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $512.10 | 2020-2024 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $270.16 | 2021-2024 | Saphnelo, Evusheld |
| Sobi, INC | $234.25 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.73 | 2019-2024 | Ofev |
| Mallinckrodt Enterprises LLC | $173.39 | 2019 | |
| Celgene Corporation | $139.63 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $136.99 | 2019-2024 | Opsumit, Uptravi |
| Medexus Pharma, INC. | $127.04 | 2019 | |
| Sanofi-Aventis U.S. LLC | $107.78 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $91.01 | 2021-2024 | Lupkynis |
| Alvogen INC | $69.13 | 2021-2023 | Teriparatide |
| Alexion Pharmaceuticals, INC. | $55.38 | 2019-2024 | Strensiq |
| Genentech USA, INC. | $49.59 | 2019-2023 | Actemra |
| Merck Sharp & Dohme LLC | $41.60 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $37.61 | 2023 | Idacio |
| Avanos Medical | $36.15 | 2021 | |
| Organon LLC | $30.18 | 2022-2024 | |
| Scilex Pharmaceuticals INC. | $19.08 | 2024 | |
| Hikma Pharmaceuticals USA | $18.24 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Korey Ullrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.